| Jul 29 |
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
|
| Jul 29 |
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
|
| Jul 23 |
7 Biotech Stocks to Keep on Your Clinical Radar
|
| Jul 23 |
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
|
| Jul 22 |
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
|
| Jul 19 |
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
|
| Jul 17 |
Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why
|
| Jul 16 |
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
|
| Jul 15 |
Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals
|
| Jul 12 |
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
|
